大分子在防治脓毒症中的研究进展。

Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou 350117, China.

Int J Mol Sci. 2023 Aug 21;24(16):13017. doi: 10.3390/ijms241613017.

Sepsis is associated with high rates of mortality in the intensive care unit and accompanied by systemic inflammatory reactions, secondary infections, and multiple organ failure. Biological macromolecules are drugs produced using modern biotechnology to prevent or treat diseases. Indeed, antithrombin, antimicrobial peptides, interleukins, antibodies, nucleic acids, and lentinan have been used to prevent and treat sepsis. In vitro, biological macromolecules can significantly ameliorate the inflammatory response, apoptosis, and multiple organ failure caused by sepsis. Several biological macromolecules have entered clinical trials. This review summarizes the sources, efficacy, mechanism of action, and research progress of macromolecular drugs used in the prevention and treatment of sepsis.

脓毒症与重症监护病房（ICU）高死亡率相关，并伴有全身炎症反应、继发感染和多器官衰竭。生物大分子是使用现代生物技术生产的药物，用于预防或治疗疾病。事实上，已使用抗凝血酶、抗菌肽、白细胞介素、抗体、核酸和香菇多糖来预防和治疗脓毒症。在体外，生物大分子可显著改善脓毒症引起的炎症反应、细胞凋亡和多器官衰竭。几种生物大分子已进入临床试验阶段。本文总结了用于脓毒症预防和治疗的生物大分子药物的来源、疗效、作用机制和研究进展。